Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data
Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data
Equillium Inc. (NASDAQ:EQ) announced Tuesday topline data from its Phase 2, single-dose, proof-of-concept (PoC) study of EQ101 in adult patients with alopecia areata.
Equillium公司（NASDAQ：EQ）周二宣布了其用于治疗斑秃患者的EQ101单剂量概念验证（PoC）II期研究的前期数据。
Alopecia is an autoimmune disease that attacks the body's hair follicles, causing patchy hair loss.
斑秃是一种自身免疫性疾病，会攻击人体的毛囊，导致局部脱发。
The primary objectives of the study were to evaluate the safety and tolerability profile of EQ101 and signs of efficacy using Severity of Alopecia Tool (SALT) scores, where a score of 100 represents total scalp hair loss and a score of 0 represents no scalp hair loss.
该研究的主要目标是评估EQ101的安全性和耐受性，以及使用斑秃严重度评分（SALT分数）的疗效表现。其中100分代表头皮全部脱发，0分代表头皮无脱发。
Study results demonstrated a favorable safety and tolerability profile. No serious adverse events and improvements in SALT scores were above the published historically low placebo response rates.
研究结果显示了EQ101具有良好的安全性和耐受性。无严重不良事件发生，并且SALT评分的改善超过了历史上低的安慰剂反应率。
Of all subjects that completed 24 weeks of treatment (baseline SALT of 35 to 100, n=25); 20% achieved a SALT score of less than or equal to 20 by week 24.
所有完成24周治疗的受试者（基线SALT为35至100，n=25）中，有20%在第24周时达到了SALT评分小于或等于20分。
Of those subjects with moderate to severe AA at baseline that completed 24 weeks of treatment (SALT score 35 to < 95, n=17), 29% achieved a SALT score of less than or equal to 20 by week 24, and a mean SALT improvement from baseline of 18%.
在所有基线为中等至重度斑秃且已完成24周治疗的受试者中（SALT评分为35至
"Placebo rates in this indication across studies have been consistently low — generally less than 10% of patients achieve a SALT score of 20 or less. To have 20% of patients completing the study reach a SALT score of less than or equal to 20 across all subjects, and 29% of moderate and severe patients, is a very encouraging sign of drug activity," said principal investigator Rodney Sinclair.
“在这种情况下，安慰剂的反应率从各项研究数据来看一直都很低，一般不到10%的患者能够达到SALT评分小于或等于20分。具有20%的受试者在所有受试者中，以及在中等和重度患者中有29%的患者达到SALT评分小于或等于20分，这是一种非常鼓舞人心的药物活性表现。”首席研究员Rodney Sinclair说。
The company says preliminary data indicate reductions of cell surface CD132 on CD8 and NK cells in peripheral blood consistent with EQ101 target engagement and pharmacodynamic response.
该公司称初步数据显示，与EQ101靶向作用和药效反应一致，外周血中CD8和NK细胞表面CD132的水平降低。
"We look forward to transitioning to a subcutaneous delivery in placebo-controlled, dose and regimen optimization studies where we expect to continue to investigate EQ101 across alopecia areata disease severity subgroups, including the important population of moderate patients with a SALT score between 35 and less than 50," said Maple Fung, chief medical officer at Equillium.
“我们期待通过皮下给药在安慰剂对照的用药方案和剂量优化研究中继续调查所有斑秃严重度亚组，包括SALT评分在35至50之间的中等患者这个重要人群。”Equillium医疗总监Maple Fung说。
Price Action: EQ shares are down 21.8% at $1.15 at last check Tuesday. During premarket trading, the shares reached as high as $1.96.
股价动态：周二最后一次检查时，EQ股票下跌21.8%，报价1.15美元。在盘前交易期间，股价最高达到1.96美元。
Now Read: Roaring Kitty's GameStop Options Could Be Worth $54M, But Cashing Out Might Be Tricky
现在阅读：Roaring Kitty的GameStop期权可能价值5400万美元，但兑现可能会很棘手